Oncology Institute Inc [TOI] stock prices are up 2.70% to $1.14 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TOI shares have gain 14.43% over the last week, with a monthly amount glided 28.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 14, 2022, and set its price target to $7. On August 15, 2022, Jefferies initiated with a Buy rating and assigned a price target of $10 on the stock.
The stock price of Oncology Institute Inc [TOI] has been fluctuating between $0.13 and $1.78 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Oncology Institute Inc [NASDAQ: TOI] shares were valued at $1.14 at the most recent close of the market. An investor can expect a potential return of 601.75% based on the average TOI price forecast.
Analyzing the TOI fundamentals
The Oncology Institute Inc [NASDAQ:TOI] reported sales of 393.41M for trailing twelve months, representing a surge of 16.88%. Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -2.73 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of8.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0035 points at the first support level, and at 0.8671 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2429, and for the 2nd resistance point, it is at 1.3459.
Ratios To Look Out For
It’s worth pointing out that Oncology Institute Inc [NASDAQ:TOI]’s Current Ratio is 2.15. Also, the Quick Ratio is 1.96, while the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 0.22, the price to book ratio is 24.06.
Transactions by insiders
Recent insider trading involved Virnich Daniel, Chief Executive Officer, that happened on Mar 26 ’25 when 22640.0 shares were purchased. Chief Medical Officer, Podnos Yale completed a deal on Mar 26 ’25 to buy 9056.0 shares. Meanwhile, Director Pacala Mark L bought 90562.0 shares on Mar 26 ’25.
